Cancer Immunotherapy with a Serotype 3 Oncolytic Adenovirus - Hemminki, Otto
39,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
20 °P sammeln
  • Broschiertes Buch

An up to date text book for anyone who is interested in the basics and history of cancer immunotherapy in general and oncolytic viruses in particular. At the time of publication the first oncolytic virus has just been granted by FDA and EMA approval and checkpoint inhibitors are gaining new indications, including melanoma, lung cancer and kidney cancer. By many, immunotherapy is considered as the most important advancement of the 21 century in the field of medicine and cancer. This book gives a thorough overview on the field. The author predicts that all cancers can be controlled by the means…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
An up to date text book for anyone who is interested in the basics and history of cancer immunotherapy in general and oncolytic viruses in particular. At the time of publication the first oncolytic virus has just been granted by FDA and EMA approval and checkpoint inhibitors are gaining new indications, including melanoma, lung cancer and kidney cancer. By many, immunotherapy is considered as the most important advancement of the 21 century in the field of medicine and cancer. This book gives a thorough overview on the field. The author predicts that all cancers can be controlled by the means of immunotherapy well before he retires. Sit back, read and learn.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
MD PhD Otto Hemminki is a member of Cancer Gene Therapy Group that designed a dozen oncolytic adenoviruses many of which were later used to treat patients with advanced cancer. Otto is an expert in cancer immunotherapy and gene therapy. At the moment Otto is specializing in urology and hoping to cure more advanced cancer patients in the future